Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

267 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Influence of HLA-G 3' Untranslated Region Haplotypes and SNP +3422 Gene Variants as Host Genetic Factors on the Outcomes of SARS-CoV-2 Infection During Acute and Post-Acute Phases in a German Cohort.
Rohn H, Elischer F, Larbig L, Jansen S, Schramm S, Otte M, Konik M, Paniskaki K, Weber P, Reinold J, Gäckler A, Krawczyk A, Wilde B, Trilling M, Michita RT, Möhlendick B, Siffert W, Brenner T, Dinse H, Skoda EM, Horn PA, Witzke O, Rebmann V. Rohn H, et al. Among authors: wilde b. HLA. 2024 Dec;104(6):e15799. doi: 10.1111/tan.15799. HLA. 2024. PMID: 39711218 Free PMC article.
Clinical characteristics and outcome of central nervous system tumors harboring NTRK gene fusions.
Lamoureux AA, Fisher MJ, Lemelle L, Pfaff E, Amir-Yazdani P, Kramm C, De Wilde B, Kazanowska B, Hutter C, Pfister SM, Sturm D, Jones DTW, Orbach D, Pierron G, Raskin S, Drilon A, Diamond EL, Harada G, Zapotocky M, Zamecnik J, Krskova L, Ellezam B, Weil AG, Venne D, Barritault M, Leblond P, Coltin H, Hammad R, Tabori U, Hawkins C, Hansford JR, Meyran D, Erker C, McFadden K, Sato M, Gottardo NG, Dholaria H, Nørøxe DS, Goto H, Ziegler DS, Lin FY, Parsons DW, Lindsay H, Wong TT, Liu YL, Wu KS, Franson AT, Hwang E, Aguilar-Bonilla A, Cheng S, Cacciotti C, Massimino M, Schiavello E, Wood P, Hoffman LM, Cappellano A, Lassaletta A, Van Damme A, Llort A, Gerber NU, Spalato Ceruso M, Bendel AE, Skrypek M, Hamideh D, Mushtaq N, Walter A, Jabado N, Alsahlawi A, Farmer JP, Coleman C, Mueller S, Mazewski C, Aguilera D, Robison NJ, O'Halloran K, Abbou S, Berlanga P, Geoerger B, Øra I, Moertel CL, Razis ED, Vernadou A, Ducray F, Bronnimann C, Seizeur R, Clarke M, Resnick AC, Alves M, Jones C, Doz F, Laetsch TW, Perreault S. Lamoureux AA, et al. Among authors: de wilde b. Clin Cancer Res. 2024 Dec 3. doi: 10.1158/1078-0432.CCR-24-0581. Online ahead of print. Clin Cancer Res. 2024. PMID: 39625867
Nakalanga syndrome and hypopituitarism.
De Wilde B, Colebunders R. De Wilde B, et al. Lancet. 2024 Nov 16;404(10466):1924-1925. doi: 10.1016/S0140-6736(24)02182-2. Lancet. 2024. PMID: 39550169 No abstract available.
Unleashing the strengths of unlabelled data in deep learning-assisted pan-cancer abdominal organ quantification: the FLARE22 challenge.
Ma J, Zhang Y, Gu S, Ge C, Mae S, Young A, Zhu C, Yang X, Meng K, Huang Z, Zhang F, Pan Y, Huang S, Wang J, Sun M, Zhang R, Jia D, Choi JW, Alves N, de Wilde B, Koehler G, Lai H, Wang E, Wiesenfarth M, Zhu Q, Dong G, He J; FLARE Challenge Consortium; Wang B. Ma J, et al. Among authors: de wilde b. Lancet Digit Health. 2024 Nov;6(11):e815-e826. doi: 10.1016/S2589-7500(24)00154-7. Lancet Digit Health. 2024. PMID: 39455194 Free article. Review.
Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial.
Lafayette R, Tumlin J, Fenoglio R, Kaufeld J, Pérez Valdivia MÁ, Wu MS, Susan Huang SH, Alamartine E, Kim SG, Yee M, Kateifides A, Rice K, Garlo K, Barratt J; SANCTUARY Study Investigators. Lafayette R, et al. J Am Soc Nephrol. 2024 Oct 25. doi: 10.1681/ASN.0000000534. Online ahead of print. J Am Soc Nephrol. 2024. PMID: 39455063 No abstract available.
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical Trial.
Gaspar N, Hung GY, Strauss SJ, Campbell-Hewson Q, Dela Cruz FS, Glade Bender JL, Koh KN, Whittle SB, Chan GC, Gerber NU, Palmu S, Morgenstern DA, Longhi A, Baecklund F, Lee JA, Locatelli F, Márquez Vega C, Janeway KA, McCowage G, McCabe MG, Bidadi B, Huang J, McKenzie J, Okpara CE, Bautista F; OLIE Study Investigators. Gaspar N, et al. JAMA Oncol. 2024 Dec 1;10(12):1645-1653. doi: 10.1001/jamaoncol.2024.4381. JAMA Oncol. 2024. PMID: 39418029 Free PMC article. Clinical Trial.
Early CYP3A5 Genotype-Based Adjustment of Tacrolimus Dosage Reduces Risk of De Novo Donor-Specific HLA Antibodies and Rejection among CYP3A5-Expressing Renal Transplant Patients.
Schönfelder K, Möhlendick B, Eisenberger U, Kribben A, Siffert W, Heinemann FM, Gäckler A, Wilde B, Friebus-Kardash J. Schönfelder K, et al. Among authors: wilde b. Diagnostics (Basel). 2024 Oct 2;14(19):2202. doi: 10.3390/diagnostics14192202. Diagnostics (Basel). 2024. PMID: 39410605 Free PMC article.
267 results